Galectin-3: a new biomarker for heart failure progression and prognosis

References

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012;125:188–97.10.1161/CIR.0b013e3182456d46Search in Google Scholar PubMed

2. Tomaschitz A, Pilz S, Pieske B, Ritz E, Marz W, Meinitzer A, et al. Circulating aldosterone and mortality in female nursing home residents. Exp Gerontol 2013;48:313–8.10.1016/j.exger.2013.01.004Search in Google Scholar PubMed

3. Tomaschitz A, Pilz S, Ritz E, Morganti A, Grammer T, Amrein K, et al. Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J 2011;32:2642–9.10.1093/eurheartj/ehr150Search in Google Scholar PubMed

4. Poletti R, Vergaro G, Zyw L, Prontera C, Passino C, Emdin M. Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. Int J Cardiol 2012; http://dx.doi.org/10.1016/j.ijcard.2012.03.061.10.1016/j.ijcard.2012.03.061Search in Google Scholar PubMed

5. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009;123:255–78.10.1016/j.pharmthera.2009.05.002Search in Google Scholar PubMed

6. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33:67–75.10.1161/ATVBAHA.112.300569Search in Google Scholar PubMed

7. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811–7.10.1093/eurjhf/hfp097Search in Google Scholar PubMed

8. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160–71.10.1111/j.1600-065X.2009.00794.xSearch in Google Scholar PubMed

9. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103:5060–5.10.1073/pnas.0511167103Search in Google Scholar PubMed PubMed Central

10. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288–98.10.2353/ajpath.2008.070726Search in Google Scholar PubMed PubMed Central

11. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007;56:57–65.10.2332/allergolint.O-06-449Search in Google Scholar PubMed

12. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217–24.10.1016/j.jacc.2006.03.061Search in Google Scholar PubMed

13. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323–8.10.1007/s00392-010-0125-ySearch in Google Scholar PubMed PubMed Central

14. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108:385–90.10.1016/j.amjcard.2011.03.056Search in Google Scholar PubMed PubMed Central

15. Ueland T, Aukrust P, Broch K, Aakhus S, Skardal R, Muntendam P, et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol 2011;150:361–4.10.1016/j.ijcard.2011.05.081Search in Google Scholar PubMed

16. Lopez-Andres N, Rossignol P, Iraqi W, Fay R, Nuee J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012;14:74–81.10.1093/eurjhf/hfr151Search in Google Scholar PubMed

17. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012;5:72–8.10.1161/CIRCHEARTFAILURE.111.963637Search in Google Scholar PubMed PubMed Central

18. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60–8.10.3109/07853890.2010.538080Search in Google Scholar PubMed PubMed Central

19. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013;15:511–8.10.1093/eurjhf/hfs205Search in Google Scholar PubMed

20. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006;1760:616–35.10.1016/j.bbagen.2005.12.020Search in Google Scholar PubMed

21. Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999;1473:172–85.10.1016/S0304-4165(99)00177-4Search in Google Scholar

22. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007;31:655–62.10.1016/j.cellbi.2006.11.036Search in Google Scholar

23. Elliott MJ, Strasser A, Metcalf D. Selective up-regulation of macrophage function in granulocyte-macrophage colony-stimulating factor transgenic mice. J Immunol 1991;147:2957–63.10.4049/jimmunol.147.9.2957Search in Google Scholar

24. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121–8.10.1161/01.CIR.0000147181.65298.4DSearch in Google Scholar

25. Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Kupper I, et al. Interferon-γ induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 2007;171:463–72.10.2353/ajpath.2007.060906Search in Google Scholar

26. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013;6:107–17.10.1161/CIRCHEARTFAILURE.112.971168Search in Google Scholar

27. Sharma U, Rhaleb NE, Pokharel S, Harding P, Rasoul S, Peng H, et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 2008;294:H1226–32.10.1152/ajpheart.00305.2007Search in Google Scholar

28. Liu YH, D’Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. N-Acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009;296:H404–12.10.1152/ajpheart.00747.2008Search in Google Scholar

29. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56–65.10.1172/JCI200522675Search in Google Scholar

30. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247–50.10.1074/jbc.275.4.2247Search in Google Scholar

31. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 1999;187:481–9.10.1002/(SICI)1096-9896(199903)187:4<481::AID-PATH263>3.0.CO;2-2Search in Google Scholar

32. Eis V, Luckow B, Vielhauer V, Siveke JT, Linde Y, Segerer S, et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 2004;15:337–47.10.1097/01.ASN.0000111246.87175.32Search in Google Scholar

33. Zandbergen HR, Sharma UC, Gupta S, Verjans JW, van den Borne S, Pokharel S, et al. Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. J Cardiovasc Pharmacol Ther 2009;14:68–75.10.1177/1074248408329860Search in Google Scholar PubMed

34. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12:826–32.10.1093/eurjhf/hfq091Search in Google Scholar PubMed PubMed Central

35. Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 2013;102:103–10.10.1007/s00392-012-0500-ySearch in Google Scholar PubMed

36. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian AS, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013;6:219–26.10.1161/CIRCHEARTFAILURE.112.000129Search in Google Scholar PubMed

37. Gopal DM, Kommineni M, Ayalon N, Koelbl C, Ayalon R, Biolo A, et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 2012;1:e000760.10.1161/JAHA.112.000760Search in Google Scholar PubMed PubMed Central

38. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 2012;164:878–83.10.1016/j.ahj.2012.08.021Search in Google Scholar PubMed